Skip to content
The Great News – Lifestyle
Home
Sample Page
Author:
Vicore Pharma Holding
Vicore’s Phase 2b ASPIRE Trial of Buloxibutid in IPF Passes Pre-Planned Futility Analysis and Remains on Track for Mid-2027 Topline Results
October 22, 2026
Vicore Pharma to Participate in the Chardan Healthcare Conference
October 13, 2026
Increase in Number of Shares and Votes in Vicore Pharma
September 30, 2026
Vicore Pharma to Present in The Stifel 2026 Virtual Immunology and Inflammation Forum
September 17, 2026
Vicore Pharma to Participate in Upcoming Healthcare Conferences
September 1, 2026
Vicore Pharma to Present at the European Respiratory Society Congress 2026
August 29, 2026
Vicore Pharma to Participate in the Leerink Therapeutics Forum
July 7, 2026
Vicore Pharma Appoints Rob Slack as Chief Scientific Officer
July 6, 2026
Vicore Pharma to Commence Trading in the United States on the Nasdaq Stock Market
July 1, 2026
Vicore Pharma to Host Webcast to Discuss Buloxibutid and the Evolving IPF Treatment Landscape
June 2, 2026
1
2
Next Page
→